Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Amur Minerals ( (GB:CRTX) ) has shared an announcement.
CRISM Therapeutics has appointed Aixial Group, a specialist clinical contract research organization, to advance its Clinical Trial Authorization application for a Phase 2 study of ChemoSeed in glioblastoma patients. The collaboration aims to expedite the CTA process and potentially include international study centers, enhancing patient recruitment and commercial prospects. Aixial’s extensive experience in rare diseases and brain tumor trials positions it as an ideal partner for CRISM, with both companies committed to advancing oncology research and improving patient outcomes.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based innovative drug delivery company that focuses on the localized delivery of chemotherapy drugs to improve the treatment of solid tumors. Its lead product, ChemoSeed, is designed for implantation directly into tumors or resection margins, particularly for high-grade glioma, offering a solution that bypasses the blood-brain barrier to effectively deliver chemotherapy drugs.
YTD Price Performance: -9.72%
Average Trading Volume: 21,534
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £1.13M
Learn more about CRTX stock on TipRanks’ Stock Analysis page.
